帕博利珠单抗诱导的腹膜后纤维化在68Ga-FAPi PET/CT上检出
本文报告一例肝细胞癌患者在接受帕博利珠单抗治疗后出现腹痛,68Ga-FAPi PET/CT显示腹主动脉旁及骶前区域FAPi高摄取软组织密度影,甲状腺弥漫性FAPi摄取增高,提示免疫检查点抑制剂诱导的腹膜后纤维化和甲状腺炎。
要点
- 肝细胞癌患者帕博利珠单抗治疗后腹痛,68Ga-FAPi PET/CT提示腹膜后纤维化。
- 影像同时见甲状腺弥漫性FAPi摄取增高,提示免疫检查点抑制剂相关甲状腺炎。
- 68Ga-FAPi PET/CT可显示免疫检查点抑制剂相关不良事件的FAPi高摄取。
核心结论
- 68Ga-FAPi PET/CT显示腹主动脉旁及骶前区域FAPi高摄取软组织密度影及甲状腺弥漫性FAPi摄取增高,提示免疫检查点抑制剂诱导的腹膜后纤维化和甲状腺炎。
研究设计与样本
- 本文为病例报告,报告一例肝细胞癌患者在接受帕博利珠单抗治疗后出现腹痛的68Ga-FAPi PET/CT表现。
主要发现
- 肝细胞癌患者开始帕博利珠单抗治疗后出现腹痛。
- 68Ga-FAPi PET/CT显示腹主动脉旁及骶前区域FAPi高摄取软组织密度影。
- 68Ga-FAPi PET/CT显示甲状腺弥漫性FAPi摄取增高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide. Immune checkpoint inhibitors (ICI) have improved progression and overall survival in patients progressing on sorafenib therapy. But activation of the immune system can lead to numerous immune-related adverse events. Here we present a case of hepatocellular carcinoma with abdominal pain after initiation of pembrolizumab. 68 Ga-FAPi PET/CT highlighted FAPi avid soft tissue density in the paraaortic and presacral regions with diffusely increased FAPi uptake in the thyroid, suggestive of ICI-induced retroperitoneal fibrosis and thyroiditis.
引用
- Agrawal N, Mahdi RA, Singh H, et al. Pembrolizumab-Induced Retroperitoneal Fibrosis Detected on 68 Ga-FAPi PET/CT. Clin Nucl Med. 2025. PMID: 40916107. doi:10.1097/RLU.0000000000006130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。